Core Viewpoint - The stock price of CSPC Pharmaceutical Group Limited (01093) experienced a decline of 2.88% on August 7, trading at HKD 9.77 per share with a transaction volume of HKD 302 million [1]. Group 1: Company Overview - CSPC Pharmaceutical Group Limited is a Hong Kong-listed pharmaceutical company primarily engaged in the production of finished drugs and active pharmaceutical ingredients, with a core development strategy focused on innovative drugs [1]. - The company has a strong product portfolio in the treatment areas of neurological diseases, oncology, anti-infection, and cardiovascular diseases [1]. - CSPC boasts an international R&D team dedicated to the discovery, research, and development of small molecule targeted drugs, nanomedicines, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and biopharmaceuticals in the immunology field [1]. Group 2: Financial Performance - As of the first quarter of 2025, CSPC Pharmaceutical Group reported total revenue of HKD 7.015 billion and a net profit of HKD 1.478 billion [2].
石药集团(01093)下跌2.88%，报9.77元/股